Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction

2003/10/01 by Eric J Rodrigues, Mark J. Eisenberg, Mark J Eisenberg +1 · 9 citations
Medicine · #ACE inhibitor #Angiotensin-converting enzyme #Blood Pressure and Hypertension Studies #Blood pressure #Cardiology #Clinical trial #Confidence interval #Heart Failure Treatment and Management #Infarction #Internal medicine #Medicine #Myocardial infarction #Odds ratio #Placebo #Randomized controlled trial #Renin-Angiotensin System Studies

paper · doi:10.1016/s0002-9343(03)00435-2

openalex publication_date 2003/10/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Cited by

• Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. [europepmc]
• Missed opportunities for the secondary prevention of cardiovascular disease in Canada. [europepmc]
• Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event. [europepmc]
• Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. [europepmc]
• Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. [europepmc]
• Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial. [europepmc]
• RAS inhibition in resident fibroblast biology. [europepmc]
• Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis. [europepmc]
• ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes: Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation. [europepmc]